Pharmaxis to Receive £2.9m from Parkinson’s UK for Phase 2 Parkinson’s Disease Clinical Trial
1st
Sep 22
Release Date: 01/09/2022 8:25am
- Ground-breaking Pharmaxis collaboration with Parkinson’s UK and leading neurologists to investigate PXS-4728 to treat patients at risk of Parkinson’s and other neurodegenerative diseases.
- The £2.9m funding comes from the Parkinson’s Virtual Biotech programme.
- Collaborators at Sydney and Oxford universities to lead the study.
- Pharmaxis team continues to deliver commercial deals leveraging expertise in inflammation.
- Clinical trial to begin recruiting patients early 2023.
Categories: News and Media